A Risk Signature Consisting of Eight m6A Methylation Regulators Predicts the Prognosis of Glioma

Guan, Sizhong; He, Ye; Su, Yanna; Zhou, Liping

doi:10.1007/s10571-021-01135-x

Cited by 10 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk score models of several prognostic signatures have been widely applied in the survival prediction of glioma ( 44 ), colon cancer ( 21 ), pancreatic ductal adenocarcinoma ( 45 ), kidney papillary cell carcinoma ( 32 ), and lung adenocarcinoma ( 43 ). This study constructed risk score models to predict the clinical outcome of HCC patients using prognosis-related lncRNAs, similar to the risk score models of other types of cancer.…”

Section: Discussionmentioning

confidence: 99%

Establishment of Prognostic Signatures of N6-Methyladenosine-Related lncRNAs and Their Potential Functions in Hepatocellular Carcinoma Patients

Deng

Liao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

N6-methyladenosine (m6a)-related mRNAs and lncRNAs have been explored for their functions in several cancers. The present study aimed to identify potential signatures of m6a-related lncRNAs in hepatocellular carcinoma (HCC). We downloaded the expression and clinical data from The Cancer Genome Atlas (TCGA) database. The interacted mRNAs and lncRNAs, prognosis-related lncRNAs, potential metabolic pathways of lncRNAs, immune infiltration of various cells, and CD274 (PD-L1) -related lncRNAs were analyzed. Then, in vitro experiments explored the role of AC012073.1 (LOC105377626) in HCC cell lines. We found that candidate 14 lncRNA signatures play functions in HCC maybe by affecting immune infiltration, cell cycle, Notch signaling pathway, etc. LncRNA AC012073.1 (LOC105377626) functions as oncogenic roles in affecting HCC prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Establishment of Prognostic Signatures of N6-Methyladenosine-Related lncRNAs and Their Potential Functions in Hepatocellular Carcinoma Patients

Deng

Liao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Further, we briefly summarized the biological functions of these transcriptional biomarkers in APOLLO. For the genes with significant main effects, the genetic variants of CHIC2 are found in brain tumor tissues, 37 and ITGAV 38 is a prognostic factor of gliomas; PLCG1 and IGF2BP2 are related to SUMOylation and m6A methylation, and involved in the immune responses, occurrence and development of gliomas; 39 , 40 , 41 MSN is an active biomarker for glioma immune regulation and a drug target. 42 For the pairs of genes with significant interactions, PRF1 is strongly associated with anti-CTLA-4 or anti-PD-L1 immunotherapy, and is related to immune cell activities and survival of gliomas.…”

Section: Discussionmentioning

confidence: 99%

APOLLO: An accurate and independently validated prediction model of lower-grade gliomas overall survival and a comparative study of model performance

Chen

Shen

et al. 2022

eBioMedicine

View full text Add to dashboard Cite

“…A recent study comprehensively investigated the m6A regulators in glioma revealed that m6A-readers were more significantly involved in the stability, translation efficiency, alternative splicing, and localization of mRNA in LGG than in GBM ( Zhao et al, 2021 ). Besides, prognostic m6A RNA methylation signatures have been constructed in CNS tumors ( Cai et al, 2021 ; Guan et al, 2021 ; Liu et al, 2021 ; Zheng et al, 2021 ; Guo F. et al, 2022 ). However, the prognostic value of other methylation signatures like 7-methylguanosine is not yet determined despite its involvement in cancer development being validated by recent studies.…”

Section: Discussionmentioning

confidence: 99%

“…A distinct pathological feature of glioma, especially GBM is the high degree of inter-and intra-tumoral heterogeneity (Gularyan et al, 2020). The above exploration of m7G regulators' expression profile and their correlation with TIMEs as well as alternative splicing events described the inter-tumoral heterogeneity in the context of RNA m7G modification.…”

Section: Intra-tumoral Heterogeneity In the Context Of M7g Regulatorsmentioning

confidence: 98%

“…In recent years, the prognostic value of RNA modification in glioma has been extensively studied. For example, m6A RNA methylation regulator-based risk models were constructed for the prediction of prognosis in astrocytoma ( Guo F. et al, 2022 ), low-grade gliomas ( Liu et al, 2021 ; Zheng et al, 2021 ), glioblastomas ( Cai et al, 2021 ), and glioma ( Guan et al, 2021 ). However, the expression pattern and prognostic value of genes related to m7G, a newly discovered form of RNA modification, remains unknown in glioma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel prognostic 7-methylguanosine signature reflects immune microenvironment and alternative splicing in glioma based on multi-omics analysis

Wang

Zhang

Jiang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Glioma is the most common type of central nervous system tumor with increasing incidence. 7-methylguanosine (m7G) is one of the diverse RNA modifications that is known to regulate RNA metabolism and its dysregulation was associated with various cancers. However, the expression pattern of m7G regulators and their roles in regulating tumor immune microenvironments (TIMEs) as well as alternative splicing events (ASEs) in glioma has not been reported. In this study, we showed that m7G regulators displayed a close correlation with each other and most of them were differentially expressed between normal and glioma tissues. Two m7G signatures were then constructed to predict the overall survival of both GBM and LGG patients with moderate predictive performance. The risk score calculated from the regression coefficient and expression level of signature genes was proved to be an independent prognostic factor for patients with LGG, thus, a nomogram was established on the risk score and other independent clinical parameters to predict the survival probability of LGG patients. We also investigated the correlation of m7G signatures with TIMEs in terms of immune scores, expression levels of HLA and immune checkpoint genes, immune cell composition, and immune-related functions. While exploring the correlation between signature genes and the ASEs in glioma, we found that EIF4E1B was a key regulator and might play dual roles depending on glioma grade. By incorporating spatial transcriptomic data, we found a cluster of cells featured by high expression of PTN exhibited the highest m7G score and may communicate with adjacent cancer cells via SPP1 and PTN signaling pathways. In conclusion, our work brought novel insights into the roles of m7G modification in TIMEs and ASEs in glioma, suggesting that evaluation of m7G in glioma could predict prognosis. Moreover, our data suggested that blocking SPP1 and PTN pathways might be a strategy for combating glioma.

show abstract

A Risk Signature Consisting of Eight m6A Methylation Regulators Predicts the Prognosis of Glioma

Cited by 10 publications

References 45 publications

Establishment of Prognostic Signatures of N6-Methyladenosine-Related lncRNAs and Their Potential Functions in Hepatocellular Carcinoma Patients

Establishment of Prognostic Signatures of N6-Methyladenosine-Related lncRNAs and Their Potential Functions in Hepatocellular Carcinoma Patients

APOLLO: An accurate and independently validated prediction model of lower-grade gliomas overall survival and a comparative study of model performance

A novel prognostic 7-methylguanosine signature reflects immune microenvironment and alternative splicing in glioma based on multi-omics analysis

Contact Info

Product

Resources

About